About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/18/2021.
 Menu
This website is for US healthcare professionals
close-icon

Log In to Bolder Science

logo-iconLog in with Doximity
or
Forgot Password

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

logo-iconLog in with Doximity
or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Specialties

Choose 1 or more specialties that you are interested in:

Subspecialties

You can specify a subspecialty for areas you selected (if available):

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/18/2021.
Previous Next skip
Our Science

    • idecabtagene vicleucel (ide-cel; bb2121; Anti-BCMA CAR T Cells)

    The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

     

    Proposed Mechanism of Action

    Ide-cel is an investigational chimeric antigen receptor (CAR) T cell therapy targeting B-cell maturation antigen (BCMA), which is expressed on the surface of normal and malignant plasma cells.1,2 The ide-cel CAR construct includes an anti-BCMA scFv-targeting domain for antigen specificity, a transmembrane domain, CD3-zeta T-cell activation domain, and a 4-1BB domain hypothesized to increase T-cell activation, proliferation, and persistence.1,3-5 Ide-cel CAR T cells are proposed to recognize and bind BCMA on the surface of plasma cells leading to apoptosis.6,7

    Ide-cel Proposed Mechanism of Action

    Ide-cel, an investigational CAR T therapy, is proposed to target BCMA on plasma cells.

    An investigational anti-BCMA (B-cell maturation antigen) CAR-T cell therapy that is being developed for the treatment of multiple myeloma by Celgene in collaboration with bluebird bio.

    idecabtagene vicleucel (ide-cel; bb2121) by Disease State

    idecabtagene vicleucel (ide-cel; bb2121) in Multiple Myeloma

    Phase 3
    3L–5L R/R multiple myeloma

    Phase 2
    4L+ R/R multiple myeloma

    Phase 2
    2L R/R multiple myeloma

    Phase 1
    High-risk newly diagnosed multiple myeloma

    View Trials Investigating idecabtagene vicleucel (ide-cel; bb2121) in Multiple Myeloma
    View Rationale for Clinical Development

    Rationale for Clinical Development

    In vitro experiments have shown that ide-cel has displayed activity against BCMA-expressing multiple myeloma, Burkitt lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, and plasmacytoma cell lines.8 Preclinical studies have demonstrated that anti-BCMA CAR T cells secrete cytokines following engagement of BCMA-expressing target cells.9

    View Related Pathways

    Chimeric Antigen Receptor (CAR) T Cells
    B-Cell Maturation Antigen (BCMA)

    References

    1. Berdeja JG, et al. J Clin Oncol. 2017;35(15 suppl):3010-3010.
    2. Seckinger A, et al. Cancer Cell. 2017;31:396-410. PMID: 28262554
    3. Davila ML, et al. Int J Hematol. 2014; 99:361-371. PMID: 24311149
    4. Bridgeman, JS, et al. Clin Exp Immunol. 2014;175:258-267. PMID: 24116999
    5. Dotti G, et al. Immunol Rev. 2014;257:107-126. PMID: 24329793
    6. Carpenter RO, et al. Clin Cancer Res. 2013;19:2048-2060. PMID: 23344265
    7. Turtle C. Int J Hematol. 2014;99:132-140. PMID: 24338745
    8. Chekmasova A, et al. Blood. 2015;126:3094.
    9. Lilley G, et al. Blood. 2015;126:3243.